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Introduction
Antibiotics have been heralded as one of the greatest contributions to modern medicine.
While antibiotics have been documented throughout many parts of the world, it was the
discovery of penicillin in 1928 that marked the modern era of medicine.1 An antibiotic is a
natural, semi-synthetic, or synthetic compound that interferes with the growth of, or results in the
death of a microorganism, specifically bacteria.2 These medications are used to treat or prevent
infection of humans or animals. With the advent of antibiotics, many infections that would cause
significant morbidity and mortality were greatly reduced. The 1930s-1960s is regarded as the
“golden age” of antibiotics, when most of the antibiotics still used today were created. 2 Since
then, there has been a dramatic slowing of antibiotic production. Several factors have contributed
to this slowing, including their short-term nature which lowers their profit potential (compared to
chronic disease medications), policies in place to reserve new antibiotics for use when current
antibiotics fail, and increased regulations regarding antibiotic production. These factors have
effectively dissuaded pharmaceutical companies from investing in novel antibiotics.3 For
example, in 2004, only 1.6% of drugs in clinical development by the world’s fifteen largest
pharmaceutical companies were antibiotics. Contrasted, antimicrobials account for more than
30% of hospital pharmacy budgets in the US.3
This is a large issue in medicine, as antibiotic resistance (ABR), or a pathogen’s ability to
evolve and withstand the effects of antibiotics, increases worldwide.4,5 Several factors contribute
to ABR including excessive use of antibiotics in humans and animals, poor sanitation, global
migration, antibiotics sold over-the-counter, and release of nonmetabolized antibiotics into the
environment through urine or feces.1 When bacteria become resistant to conventional treatments,
more expensive, and toxigenic drugs are needed to combat them. Compared to susceptible
bacterial infections, resistant infections are associated with an increase in morbidity, mortality
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and prolonged hospital stay.4,5,6 The burden of ABR on society and their respective economies
cannot be understated. In the US alone, antibiotic resistant hospital acquired infections cause
99,000 deaths annually, a total of $20 billion in economic losses annually, and a loss of $35
billion annually due to productivity loss.1
It has been estimated that the burden of ABR in developing countries is even higher due
to lack of resources.4,6 For example, in developed countries like the US, resistant bacterial
infections may be treated with vancomycin or imipenem, which are more effective, but have
increased cost and side effects. When contrasted in developing countries, many cannot afford
these expensive treatments, preventing them from being readily available to the public.6
Streptococcus Pneumoniae (S. Pneumoniae) is a gram-positive organism which is
responsible for several bacterial infections in humans. 7 90 serotypes exist to date and the 10 most
common account for approximately 62% of invasive disease worldwide. 7 S. Pneumoniae is the
leading cause of pneumonia, meningitis, and bacteremia in adults and children. It is also the
leading cause of otitis media (OM) in infants and children worldwide.7,8 Pneumonia is the most
common cause of death in children younger than 5 years, with 1.6 million deaths occurring
annually.8 People more likely to be infected with pneumococcal disease are children less than 2,
adults 65 years or older, those with chronic conditions such as pulmonary disease, and those with
immunosuppression.8 Pediatricians, geriatricians, and internists have an obligation to stay current
on data regarding ABR S. Pneumoniae given their susceptible populations.
S. Pneumoniae have become ABR to conventional treatments, including beta-lactams,
macrolides, tetracycline, trimethoprim-sulfamethoxazole (TMP-SMX), erythromycin and
others.9 This is a trend worldwide and developing countries deserve special attention. Unlike
developed countries like the US, there remain many barriers to effectively treating ABR S.
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Pneumoniae infections such as cost of treatment, inaccessibility of healthcare and lack of
infrastructure to analyze trends of ABR. This paper aims to identify some of the contributors to
ABR S. Pneumoniae in developing countries with special attention to Latin America. In addition,
this paper will explore some strategies that developed countries use to reduce or control ABR
which developing countries can model.
Background
Antibiotic Use in Food and Animal Agriculture
One of the largest contributors to ABR is the use of antibiotics in agriculture. While S.
Pneumoniae is human specific, and has no animal vector, the concept of antibiotic use in
agriculture is still worth investigating due to its large impact on a global scale. Concomitant
infection of S. Pneumoniae with ABR pathogens related to agriculture are possible and pose
serious risk.
Antibiotic use puts selective pressure on bacteria, eliminating susceptible bacteria while
favoring the survival of resistant strains that have physiologic protective mechanisms against
them. In agriculture, not only are antibiotics used for treatment of livestock, but also for
proactive purposes. In metaphylaxis, if a farmer sees disease symptoms in one animal, they will
treat all other animals with an antibiotic to prevent spread of that disease. Physiologic stress is
commonly experienced by livestock due to their living conditions, which can cause
immunosuppression. In order to combat this, farmers will often utilize prophylactic treatments,
where a sub-therapeutic dose of an antibiotic is given to the immunocompromised animals to
prevent infection.2
Antibiotics have also been used in agriculture as a growth promoter leading to rapid
growth in food animals and fish, while also contributing to an increase in ABR.2 This is a
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frightening realization, as humans can become infected from ABR pathogens indirectly along the
food chain through ingestion of food products or directly from colonized biological substances
from animals such as blood, urine, feces, saliva and semen.2 Given the expansion of the global
population, globalization of trade (especially food animals) and international travel, this is a
problem that extends beyond borders. Every nation can be affected by this mounting issue. For
this reason, it is imperative that local, regional, national and international regulations be put in
place to monitor and regulate ABR.
Developed countries, such as Denmark, Sweden, and the US have systems and programs
in place to monitor antibiotic use in agriculture and ABR in food animals and products.2
Developed countries such as these can analyze trends and implement national-level regulations
to reduce the use of antibiotics in this sector. Denmark, for example, banned avoparcin in 1995,
and in 2008 it was found that poultry production increased slightly, while reducing antibiotic
consumption by 90%.2 These surveillance systems have proven to be effective in the
management of antibiotic use in agriculture.
In contrast to developed countries, most developing countries have no systems or
programs that monitor antibiotic use or ABR in agriculture.2 In developing countries, there seems
to be a large emphasis on antibiotic use for growth-promotion. A study by Eagar et. al.
determined that two thirds of 1500 tons of antibiotics sold for animal use in South Africa over a
three-year period were for growth-promotion purposes.2 It is also estimated that from 2010 to
2030, up to a third of the global increase in antibiotic consumption in food animals will be
attributed to lower-middle income countries.2 This is alarming as the majority of developing
countries are major exporters of animals and their products. Brazil, for example, is the world’s

6

largest exporter of chicken meat.2 Any ABR bacteria seen in the chickens of that region, will
surely reach across the globe.
Unrestricted Access and Self-Medication
One of the unique challenges that developing countries face regarding ABR is the
unrestricted access to antibiotics. It is known that justified and controlled use of antibiotics
contributes to ABR, however, widespread and unnecessary use exacerbates the situation. In
many developing countries, the public have access to antibiotics over the counter without the
need of a prescription. This problem is exacerbated by the fact that many of these antibiotics are
acquired through unregulated supply chains.10,11 In general, the public acquires antibiotics from
non-professional sources and their education surrounding when an antibiotic is indicated, how
much to take, the side effects associated with them, and the duration of use is lacking. 10,11
To make factors worse, when antibiotic use is recommended, locals often prefer
treatment from traditional healers who provide herbal supplements. 11 This is especially true in
rural areas, where many do not have adequate access to healthcare. While studying abroad in
Costa Rica on July 7th, 2019, a rural resident of Longo Mai named Mercedes reported her
preferences regarding treatment of illnesses, “I always prefer natural medicine over going to the
doctor. This is because doctors give us chemicals which are bad for us. Also, it is at least 30
minutes to the nearest clinic in Buenos Aires. I always choose natural medicine”. The
composition and potency of these herbal remedies are unknown, therefore, the effects they exert
on pathogens are also unknown. It is plausible these herbal remedies might produce
antimicrobial effects, but, if given at sub-therapeutic doses, may confer ABR.11
Self-medication practices have been shown to be excessive in Latin American
countries.10 Several authors have attributed high prevalence of self-medication with antibiotics to

7

poor access to healthcare in several countries, such as Costa Rica, Nicaragua, Chile, Argentina,
Brazil, and Colombia.10 Many developing countries, especially those in Latin America, seem to
prefer unrestricted access to antibiotics in an effort to maintain reasonable access to medications.
This is due to a recognition that if regulations were put in place, many would not have adequate
access to receive the medications they may need.10 A study done in Guatemala by Ramay et. al.
in 2015 revealed the top four antibiotics used in self-medication were: amoxicillin, tetracycline,
TMP-SMX, and erythromycin. (Table 1)10 These are some of the first line medications used in
the treatment of S. Pneumoniae infections, which is problematic.
ABR Serotypes and Pneumococcal Conjugate Vaccine
Although all pneumococcal infections can be treated with antibiotics, the available
choices are limited for some strains. While antibiotics are used as a reactive approach to
treatment of bacterial infections, vaccinations are a proactive approach to prevent bacterial
infections from happening in the first place. Pneumococcal conjugate vaccines (PCVs) are
effective against invasive pneumococcal disease (IPD) and have a significant effect directly on
those who acquire them as well as indirectly.8
In the US, multi-drug resistant strains of S. Pneumoniae were first isolated in children
and are predominantly associated with pediatric serotypes (6A, 6B, 9V, 14, 19A, 19F and 23F).8
Because of the pneumococcal vaccine, less multi-drug resistant strains of S. Pneumoniae were
reported in the US within 14 years of its introduction. A shift of multi-drug resistant strains has
now been reported in serotypes 15A, 15B, 15C, 6C, 23A, and 35B. Multi-resistant serotype 19A
isolates are still reported with the highest resistance to beta-lactams, macrolides, tetracycline, cotrimoxazole and lincosamides.8 Just 4 years after the introduction of the pneumococcal conjugate
vaccine-7 (PCV-7) in 2000, which covers the most common ABR serotypes (4, 6B, 9V, 14, 18C,
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19F, and 23F) the US witnessed a decrease in penicillin-resistant S. Pneumoniae infections from
6.3 to 2.7 per 100,000, and multi-drug resistant S. Pneumoniae infections (4.1 to 1.7 cases per
100,000). (Figure 1)8 Vaccine-type resistant S. Pneumoniae disease decreased by 87% following
the introduction of the PCV-7 in the US.8 Similar findings can be seen throughout the world. For
example, after the introduction of the PCV-10 in Brazil, there was a decrease in penicillin and
ceftriaxone resistant S. Pneumoniae infections.
In Latin America, most ABR S. Pneumoniae infections are caused by serotypes 6A, 6B,
9V, 14, 19A, 19F, and 23F. Serotype 23F, a clonal serotype from Spain, which is resistant to
penicillin, chloramphenicol, tetracycline and erythromycin, has had a large impact on this
region.6,9 These serotypes reflect similar trends in developed countries such as the US. In Latin
America, countries with the highest percentage of penicillin-resistant isolates are Puerto Rico
(35%) and Peru (27%). The highest median percentage of S. Pneumoniae isolates with highlevel resistance was found in children less than 5 years of age. Mexico reported the highest rate
of penicillin-resistant pneumococcal isolates (22%) and 47% overall ABR. Argentina reported
the highest penicillin resistant OM isolates (80%). It is worth noting that OM represents 79% of
all infections caused by S. Pneumoniae in Latin America and the Caribbean. Consequently, this
results in most of the consumption of antibiotics in the region.9 Providing PCVs in this region is
therefore of utmost importance.
Unfortunately, many developing countries, and Latin American countries specifically, do
not have adequate access to these vaccines. For example, the PCV-7 became available to Costa
Rica in 2004. While this is beneficial for the country, it was estimated that only 10-15% of
children in Costa Rica had access to this vaccine.12 This was attributed to economic limitations,
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leaving the vaccine available only to children who had private insurance. Proper access to PCVs
in developing countries would decrease the burden of pneumococcal disease as well as ABR.
Clinical Practice Guidelines, Surveillance and Improper Prescribing Practices
In modern medicine, the use of empirical treatment guidelines for specific infections is an
important part of quality healthcare. The same is true for S. Pneumoniae infections. In developed
countries such as the US, societies like the Infectious Disease Society of America and the
American Thoracic Society (IDSA/ATS) have provided specific treatment guidelines for
practitioners to use in the treatment of pneumonia infections.14 These guidelines are generated
based upon current data highlighting effective antimicrobial agents. In the US, pneumococcal
disease data is constantly monitored using the population-based survey system called Active
Bacterial Core Surveillance Program (ABC).8 The US then uses this data to update and educate
medical providers on trends of ABR pneumococcal disease and provide appropriate treatment
guidelines.
According to the IDSA/ATS, recommended treatment guidelines for pneumonia are:
macrolide or doxycycline in a previously healthy person with no risk factors for ABR S.
Pneumoniae infection, a respiratory fluoroquinolone or beta-lactam plus a macrolide if the
patient has comorbidities such as heart disease or been previously exposed to antibiotics in the
previous 3 months, and use of the previous agents mentioned if local macrolide-resistant S.
Pneumoniae infections are prevalent (>25%).8 Guidelines, therefore, depend on adequate
surveillance in order to be effective.
Many Latin American countries do not have adequate surveillance systems in place to
make proper treatment guidelines for their area. Because of this, much of the rudimentary data in
these countries are based solely on point-prevalence assessments or case studies.6 For this
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reason, the IDSA/ATS guidelines for pneumococcal disease have been used by Latin American
countries as a reference for treatment.14 While this is a valuable resource and much of the trends
of pneumococcal infections and ABR patterns in the US have been similar in Latin American
countries, proper prescribing practices are necessary on the part of medical providers.
A study done in 2015 by Gattarello et. al. demonstrated that when physicians from Latin
American countries were given fictional patient cases with community-acquired pneumonia
(CAP) and nosocomial pneumonia, 31% of CAP cases and only 3% of nosocomial pneumonia
cases were considered adequate treatments following the IDSA/ATS guidelines. (Table 2)14 This
reflects the need for not only proper surveillance and guidelines in Latin American countries, but
for adequate and ongoing education for medical providers. Without continuing education,
medical providers will continue to prescribe improper treatments for S. Pneumoniae infections,
further contributing to burden of disease and ABR.
Methods
This was a literature review conducted using PubMed. A search was done using
keywords such as “antibiotic resistance, Streptococcus Pneumoniae, developing countries, Latin
America, Costa Rica and clinical guidelines”. Initially, 27 articles were collected and filtered
based upon relevance to the topic, date of publication and redundancy of information to other
articles used during June and July of 2019. Fourteen articles were used in this literature review.
Some government websites were utilized for general background information on healthcare. A
brief interview was conducted with Mercedes, a resident of a rural community called Longo Mai
in Costa Rica, regarding her opinion on healthcare and antibiotics. Another interview was
conducted with Dr. Jose Alejandro Madrigal Lobo, a member of the Costa Rican Doctor’s
Association regarding the healthcare system in Costa Rica.
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Discussion
While modern medicine has made large impacts on global health, finances are a
consistent barrier to adequate access to healthcare. Specifically, the advent of antibiotics
introduced new challenges to the medical community. Antibiotics are a mainstay to the treatment
of infectious disease but have contributed to global ABR pathogens. As previously stated, ABR
infections increase morbidity and mortality worldwide, require constant surveillance and
necessitate novel treatments. Countries in Latin America are still considered developing and just
don’t have the ability to combat ABR like developed countries. While barriers exist, small policy
changes could have positive impacts on these countries.
Winning the battle with ABR infections such as S. Pneumoniae require national and
international efforts. Surveillance systems that monitor ABR patterns from major regions
throughout the country will determine proper therapeutic guidelines. While many Latin
American countries do not have this in place, it is a goal that should be worked on to improve
outcomes regarding ABR infections. Placing surveillance programs at large tertiary hospitals
throughout Latin American countries where proper microbiological testing is available could
help the situation. When patients with severe infections go to the hospital, often they will receive
cultures and other laboratory tests to determine the nature of the disease. Implementing a
recording program in these countries could help better understand local and regional patterns of
ABR.
While many medical providers have understanding regarding treatments for common
infections, it is apparent that many do not stay current with therapeutic guidelines, especially
more complex cases. Continuing education for medical providers is imperative so they can make
the best recommendation for their patients. International cooperation from medical providers in

12

developed, high-income countries may be a feasible way to ensure medical providers in
developing countries like Latin America stay current on treatment guidelines.
Antibiotic use in agriculture is a large issue in developing countries that has major
implications across the world. As previously stated, S. Pneumoniae is a human-only pathogen
and doesn’t reside in animals, however, due to the global implications of antibiotic use in
agriculture, and the risk of multiple infections, it is important to address. Developing countries
could benefit from the replication of models used in developed countries. While there are
barriers to implementing complex infrastructure involving cost and human resources, it is a goal
that is imperative to achieve. One policy that could be implemented in developing countries is
restricting access of antibiotics to farmers. Currently, most developing countries do not require
veterinarian oversight to access antibiotics. Adding nation-wide regulations that strictly prohibit
access to antibiotics without veterinary oversight in developing countries like Latin America
could be a step towards effective management of this issue. Also, providing farmers with
education surrounding ABR is important. Countries should also implement policies that restrict
the use of antibiotics as growth promoters, like many developed nations.
The use of over-the-counter antibiotics for human consumption is another issue that
needs to be addressed in developing countries. Uneducated and unrestricted use of antibiotics can
contribute to ABR in S. Pneumoniae infections. The absence of healthcare professionals in
pharmacies and lack of regulations for antibiotic prescriptions is a contributing factor. If the role
of the pharmacist became more integral to the acquisition of antibiotics, patients would likely
become more educated surrounding them.10 In order to do this, developing countries need to
develop laws that regulate the dispensing of medications. Like many developed countries that
require prescriptions for acquisition of antibiotics, a stricter policy along with the integration of
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pharmacists would improve safety, rational use, and affordability of antibiotics.10,11 One might
question how policies introducing more regulations would be cost effective. Up front cost would
surely rise, but the benefits it would impose by decreasing overall ABR infections, the need for
more invasive and costly treatments, and hospitalizations would make up for upfront costs.
Vaccine programs are important for protection of the population and prevention of ABR
pneumococcal infections. While implementing PCVs in developing countries like Latin America
may be difficult due to financial constraints, it is still important to continue to advocate for them.
Pneumococcal disease represents a large majority of infectious disease across the world. With
the introduction of the PCV-7 vaccine in the United States, pneumococcal infections dropped
significantly. Much of the cost required to treat those who become infected is therefore abated.
Research on cost-effective implementation of vaccines in developing countries will be more
productive than treatment of pneumococcal infections themselves.
Conclusion
ABR is a global issue and persists despite advanced efforts to control it. This is
compounded by the fact that there has been little development of new antibiotics to combat this.
ABR infections pose significant morbidity and mortality worldwide as conventional antibiotics
have become less effective. This is especially true for S. Pneumoniae, which as previously stated
causes most invasive disease worldwide. The problem of ABR S. Pneumoniae becomes
exponential in developing countries where they lack the proper resources to implement
surveillance infrastructure to track ABR, development of proper guidelines based upon local
data, education for medical providers on current empiric treatment guidelines, access to
vaccinations and more costly treatments. These problems are further exacerbated by the high
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prevalence of self-medication of antibiotics which are frequently acquired over-the-counter,
without education regarding these medications.
ABR is an issue that spans across borders and global efforts should be implemented to
improve these disparities for developing countries such as Latin America. Joint global funding,
research, and education guidelines could be implemented in developing countries to improve
outcomes, with a priority to common infectious diseases that cause significant morbidity and
mortality, such as S. Pneumoniae. Understanding the disparities that developing countries face
regarding ABR is an instrumental part to the creation of a solution. Now that many disparities
are understood, implementation of nation-wide policies aimed at reducing ABR needs to be
investigated. It is easy to say such policies need to be created but the actual implementation of
them is far more challenging. Future research should focus on feasible ways to implement the
strategies outlined in this paper to improve healthcare in developing countries. Even small
changes in policy will help decrease ABR and improve global health.
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Appendices
Table 1. Reported most common antibiotic purchases when self-medicating.10

Table 2. Antibiotic prescription, dose and duration in the case of CAP. 14
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Figure 1. ABCs IPD rates in 1999, 2009 (9 years after PCV7 introduction), and 2013 (3 years after PCV13
introduction).8
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